Acrivon Therapeutics, Inc. (ACRV) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Acrivon Therapeutics, Inc. (ACRV) closed at USD 1.76 on 2026-10-15, a change of -6.9 % over the past year, with a market capitalization of USD 70.28M.
Acrivon Therapeutics, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-15 | 1.76 |
| 2026-10-14 | 1.72 |
| 2026-10-13 | 1.75 |
| 2026-10-12 | 1.90 |
| 2026-10-09 | 1.91 |
| 2026-10-08 | 1.87 |
| 2026-10-07 | 1.88 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Acrivon Therapeutics, Inc. key figures
- Previous close
- USD 1.76 (2026-10-15)
- 1-year change
- -6.9 %
- Market cap
- USD 70.28M
- Enterprise value
- USD -17.56M
- P/E ratio (trailing)
- -0.87
- P/E ratio (forward)
- -1.00
- EPS (trailing)
- -1.88
- EPS (forward)
- -1.64
- PEG ratio
- n/a
- Price to book
- 0.81
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 5.30
- Employees
- 74
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Acrivon Therapeutics, Inc. and compare it with other stocks.
Analyze ACRVAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Acrivon Therapeutics, Inc. shares.